相关临床试验
0
0 进行中
药物批准
45
批准总数
监管机构
2
监管机构数
成立时间
N/A
暂无试验阶段数据
暂无试验数据
暂无试验数据
- A modeling study in The Lancet projects Medicare's most-favored-nation pricing policy would cut spending by $5.2 billion under GLOBE and $6.4 billion under GUARD in its initial phase. - For roughly three in four medicines studied, Medicare savings would approach four times that drug's entire annual sales in the reference country, creating incentives to alter pricing abroad. - Reported confidential agreements with 17 manufacturers could reduce the policy's projected Medicare savings by 71 percent, according to the analysis. - The White House separately announced that all 50 state Medicaid programs will receive most-favored-nation rebates on brand-name drugs, with taxpayer savings estimated at $64.3 billion over a decade.
- PeproMene Bio's BAFF-R-targeted CAR T-cell therapy PMB-CT01 achieved complete responses in seven of nine heavily pretreated relapsed or refractory B-cell non-Hodgkin lymphoma patients in Phase 1. - Four of six patients who had progressed after prior CD19-directed CAR T-cell therapy responded, with all complete responses ongoing at data cutoff and the longest exceeding 35 months. - All cytokine release syndrome events and the two reported ICANS events were Grade 1 only, a profile the company says may support future outpatient administration. - The Institute for Follicular Lymphoma Innovation committed up to USD 11 million in December 2024 to support PMB-CT01 development in relapsed or refractory follicular lymphoma.
- Andera Partners, managing over $6 billion, uses a stage-diversified single-fund model spanning early-stage creation (20%), mid-stage Series B to phase one (50%), and late-stage public-market plays (30%). - Litzka argues biotech companies fail more often from "bad reasons" — operational, regulatory, and communication breakdowns — than from bad science, and boards must help companies "fail for the good reasons." - The Tupolis ADC pivot exemplifies the philosophy: the Munich company shifted from a weak clinical program to its versatile linker technology and was acquired by Gilead in 2026. - Litzka offers a measured view of AI as a productivity tool in patient preselection and compound selection, while warning that China's fast-moving ADC machinery poses a serious competitive threat.
- Oryon Cell Therapies has appointed Kenny Choi, Ph.D., as Chief Technical Officer to lead technical operations and CMC strategy for its autologous neuron replacement medicines. - Dr. Choi brings more than fifteen years of cell therapy manufacturing experience, contributing to over a dozen INDs and three BLAs for autologous cell therapies. - He will oversee transfer of the autologous iPSC-derived dopaminergic neuron manufacturing process from Mass General Brigham to Oryon's own facilities for late-stage development and commercial launch. - Oryon's lead program is in a Phase 1/2a trial for Parkinson's disease, with interim data showing sustained motor improvements in all treated participants.
- Island Pharmaceuticals received regulatory and ethics approvals for compassionate use of galidesivir in the Bundibugyo Ebola outbreak, with deployment expected in Uganda this year. - Galidesivir is a broad-spectrum antiviral delivered intravenously that blocks viral replication; early healthy-volunteer studies found it generally safe and well tolerated. - The drug will be studied under the WHO's MEURI framework, enabling prospective collection of clinical, safety, and virological data during the public health emergency. - Currently no approved vaccines or treatments exist for Bundibugyo Ebola virus disease, and the outbreak has caused 20 confirmed cases and two deaths in Uganda.
- A Northwestern Medicine study reveals that radiotherapy fundamentally reshapes the immune ecosystem within cutaneous T-cell lymphoma (CTCL) tumors beyond simply killing cancer cells. - Researchers used spatial transcriptomics and a novel non-invasive skin tape-strip method to track molecular changes before and after radiotherapy in CTCL patients. - Tumors that recurred within one year showed increased radiation resistance genes and persistent inflammation, while remission tumors exhibited stronger interferon signaling and sustained humoral immune activation. - The findings open opportunities for combination therapies that enhance anti-tumor immunity and bring precision medicine closer to routine clinical care for CTCL.
- Kite and the American Cancer Society announced a renewed program to reduce non-clinical barriers to CAR T-cell therapy for blood cancer patients nationwide. - Only two out of ten eligible patients currently receive CAR T-cell therapy, highlighting a significant access gap the partnership aims to close. - Year-one achievements included a CAR T Caregiver Financial Assistance Fund providing grants across 16 states and a landmark national survey identifying caregiver support gaps. - The expanded second phase will strengthen support infrastructure from diagnosis through survivorship by expanding financial assistance and accelerating best practices across treatment centers.
- A new review examines rare histological subtypes of triple-negative breast cancer (TNBC), which account for 10–15% of all TNBC cases and exhibit distinct biological behaviors and treatment responses. - The review emphasizes that standard TNBC treatment approaches may not be appropriate for all rare subtypes, with some requiring tailored therapeutic strategies based on unique molecular profiles. - Key rare subtypes discussed include metaplastic, adenoid cystic, medullary, and secretory carcinomas, each presenting unique diagnostic challenges and prognostic considerations. - The authors call for increased awareness among pathologists and oncologists to ensure accurate diagnosis and optimal treatment selection for patients with these uncommon malignancies.
- Cencora has entered a major U.S. distribution partnership with Kite Pharma, a Gilead company, to support FDA-approved CAR T cell therapies across treatment centers. - The agreement focuses on market access and distribution support, aiming to ease logistical and administrative hurdles for healthcare providers using these personalized cancer treatments. - The collaboration highlights Cencora's growing role in complex therapy and specialized distribution, potentially influencing how investors view its position in next-generation treatment logistics. - Cencora's stock trades at $279.57, roughly 25% below the $350.58 analyst consensus target, with shares flagged as undervalued at 42.6% below estimated fair value.
- The average biopharmaceutical employee earned $116,648 in 2025, roughly 30% more than the average S&P 500 worker at $89,744, according to an Endpoints News study. - Gilead topped Big Pharma with a median salary of $239,000, while biotech firms like Alnylam ($312,000) and Ionis ($305,000) far exceeded even the most generous large drugmakers. - Johnson & Johnson, the industry's perennial revenue leader, ranked only 10th in median salary at $91,000, demonstrating that company size and profitability do not directly correlate with employee pay. - The 32 large biotech companies studied collectively employ over one million people with a combined market capitalization of $3.88 trillion.
